Hepatitis C, Chronic
405
2
6
311
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
184 trials with published results (45%)
Research Maturity
311 completed trials (77% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
10.1%
41 terminated out of 405 trials
88.4%
+1.8% vs benchmark
36%
144 trials in Phase 3/4
59%
184 of 311 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 311 completed trials
Clinical Trials (405)
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
Linkage to Care for Persons With Hep C Infection
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients
Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Integrated Treatment of Hepatitis C Virus Infection
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.